Literature DB >> 18311557

Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice.

Ming-Huan Chan1, Pao-Hsiang Chiu, Jen-Hou Sou, Hwei-Hsien Chen.   

Abstract

RATIONALE: Recent studies have shown that metabotropic glutamate receptor 5 (mGluR5) can modulate N-methyl-D-aspartate receptor function. Our previous findings demonstrated that the selective mGluR5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) and the antagonist 2-methyl-6-(phenylethynyl)-pyridine can reduce and enhance the ketamine anesthesia, respectively.
OBJECTIVE: The purpose of this study was to examine whether CHPG and positive allosteric modulator 3,3'-difluorobenzaldazine (DFB) can reverse ketamine-induced behavioral responses including locomotor hyperactivity, motor incoordination, sensorimotor gating deficit, and learning impairment.
METHODS: Mice were pretreated with CHPG (5-50 nmol,) or DFB (40-100 nmol) followed by ketamine administration. Locomotor activity, rotarod test, prepulse inhibition (PPI) of acoustic startle test, and novel object recognition test were examined.
RESULTS: CHPG and DFB had no effect on these behaviors when administered alone. Both of them attenuated the locomotor hyperactivity, motor incoordination, and cognitive impairment induced by ketamine. However, the ketamine-induced PPI deficit was reversed by CHPG (50 nmol) but not by DFB (up to 100 nmol). CHPG and DFB have distinct potency and efficacy in attenuating ketamine-induced behavioral response.
CONCLUSIONS: These behavioral data extend previous findings and further suggest that positive modulation of mGluR5 may provide a novel approach for development of antipsychotic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311557     DOI: 10.1007/s00213-008-1103-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.

Authors:  H Awad; G W Hubert; Y Smith; A I Levey; P J Conn
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

2.  Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

Authors:  A K Malhotra; D A Pinals; C M Adler; I Elman; A Clifton; D Pickar; A Breier
Journal:  Neuropsychopharmacology       Date:  1997-09       Impact factor: 7.853

3.  Regulation of phosphorylation of NMDA receptor NR1 subunits in the rat neostriatum by group I metabotropic glutamate receptors in vivo.

Authors:  Eun Sang Choe; Eun Ha Shin; John Q Wang
Journal:  Neurosci Lett       Date:  2005-11-21       Impact factor: 3.046

4.  Activation of group I mGluRs potentiates NMDA responses in rat hippocampal slices.

Authors:  S M Fitzjohn; A J Irving; M J Palmer; J Harvey; D Lodge; G L Collingridge
Journal:  Neurosci Lett       Date:  1996-01-26       Impact factor: 3.046

5.  Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice.

Authors:  Hiroyuki Kamei; Taku Nagai; Hiroko Nakano; Yuriko Togan; Masanori Takayanagi; Kenji Takahashi; Kana Kobayashi; Shigeru Yoshida; Kenji Maeda; Kazuhiro Takuma; Toshitaka Nabeshima; Kiyofumi Yamada
Journal:  Biol Psychiatry       Date:  2005-09-01       Impact factor: 13.382

6.  Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.

Authors:  A Pisani; P Gubellini; P Bonsi; F Conquet; B Picconi; D Centonze; G Bernardi; P Calabresi
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

7.  Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents.

Authors:  Gene G Kinney; Maryann Burno; Una C Campbell; Lisa M Hernandez; Dana Rodriguez; Linda J Bristow; P Jeffrey Conn
Journal:  J Pharmacol Exp Ther       Date:  2003-03-26       Impact factor: 4.030

8.  The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices.

Authors:  Feng Liu; Guoming Zhang; Geoffrey Hornby; Dmytro Vasylyev; Mark Bowlby; Kaapjoo Park; Adam Gilbert; Karen Marquis; Terrance H Andree
Journal:  Eur J Pharmacol       Date:  2006-04-05       Impact factor: 4.432

9.  Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo.

Authors:  Craig W Lindsley; David D Wisnoski; William H Leister; Julie A O'brien; Wei Lemaire; David L Williams; Maryann Burno; Cyrille Sur; Gene G Kinney; Doug J Pettibone; Philip R Tiller; Sheri Smith; Mark E Duggan; George D Hartman; P Jeffrey Conn; Joel R Huff
Journal:  J Med Chem       Date:  2004-11-18       Impact factor: 7.446

10.  A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.

Authors:  Julie A O'Brien; Wei Lemaire; Tsing-Bau Chen; Raymond S L Chang; Marlene A Jacobson; Sookhee N Ha; Craig W Lindsley; Hervé J Schaffhauser; Cyrille Sur; Douglas J Pettibone; P Jeffrey Conn; David L Williams
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

View more
  22 in total

Review 1.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

2.  Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats.

Authors:  S W Fowler; A K Ramsey; J M Walker; P Serfozo; M F Olive; T R Schachtman; A Simonyi
Journal:  Neurobiol Learn Mem       Date:  2010-11-17       Impact factor: 2.877

Review 3.  Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Shaun R Stauffer
Journal:  ACS Chem Neurosci       Date:  2011-06-27       Impact factor: 4.418

4.  Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors:  Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2020-01-11       Impact factor: 4.530

5.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

6.  Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).

Authors:  María Luz Martín-Martín; José Manuel Bartolomé-Nebreda; Susana Conde-Ceide; Sergio A Alonso de Diego; Silvia López; Carlos M Martínez-Viturro; Han Min Tong; Hilde Lavreysen; Gregor J Macdonald; Thomas Steckler; Claire Mackie; Thomas M Bridges; J Scott Daniels; Colleen M Niswender; Meredith J Noetzel; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2015-01-28       Impact factor: 2.823

7.  The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.

Authors:  Hwei-Hsien Chen; Astrid Stoker; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2010-03-10       Impact factor: 4.530

Review 8.  Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.

Authors:  Meredith J Noetzel; Carrie K Jones; P Jeffrey Conn
Journal:  Discov Med       Date:  2012-11       Impact factor: 2.970

9.  Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice.

Authors:  Jen-Cheng Lin; Mei-Yi Lee; Ming-Huan Chan; Yi-Chyan Chen; Hwei-Hsien Chen
Journal:  Psychopharmacology (Berl)       Date:  2016-06-30       Impact factor: 4.530

10.  mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning.

Authors:  Jennifer E Ayala; Yelin Chen; Jessica L Banko; Douglas J Sheffler; Richard Williams; Alexandra N Telk; Noreen L Watson; Zixiu Xiang; Yongqin Zhang; Paulianda J Jones; Craig W Lindsley; M Foster Olive; P Jeffrey Conn
Journal:  Neuropsychopharmacology       Date:  2009-03-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.